

Note: In the certification process, some certificants used software developed by other firms and may not be holding themselves out to file tariffs for the public, generally.

Joseph T. Farrell,

Acting Secretary.

[FR Doc. 95-9548 Filed 4-18-95; 8:45 am]

BILLING CODE 67301-01-M

FEDERAL RESERVE SYSTEM

Community Capital Corporation, et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than May 12, 1995.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Community Capital Corporation*, Greenwood, South Carolina; to acquire 100 percent of the voting shares of Clemson Bank & Trust, Clemson, South Carolina (in organization).

B. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *First Grayson Bancshares, Inc., Employee Stock Ownership Plan*, Whitesboro, Texas; to become bank holding company by acquiring 15.82 percent of the voting shares of First Grayson Bancshares, Inc., Whitesboro, Texas, and thereby indirectly acquire

Security Bank of Whitesboro, Whitesboro, Texas.

2. *Metroplex North Bancshares, Inc., Employee Stock Ownership Plan*, Whitesboro, Texas; to become a bank holding company by acquiring 17.87 percent of the voting shares of Metroplex North Bancshares, Inc., Whitesboro, Texas, and thereby indirectly acquire The First Bank of Celeste, Celeste, Texas.

Board of Governors of the Federal Reserve System, April 13, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-9634 Filed 4-18-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Clinical Laboratory Improvement Advisory Committee.

Times and Dates: 8:30 a.m.-4:30 p.m., May 10, 1995; 8 a.m.-3:30 p.m., May 11, 1995.

Place: CDC, Auditorium A, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include an update from CDC on the implementation of the Clinical Laboratory Improvement Amendments, including the current process for reviewing tests for waived status, a discussion of the ongoing review of the regulatory burden and benefits of laboratory personnel requirements, and quality control standards.

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: John C. Ridderhof, Dr.P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway,

NE., Mailstop G-25, Atlanta, Georgia 30341-3724, telephone 404/488-7660.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-9618 Filed 4-18-95; 8:45 am]

BILLING CODE 4163-18-M

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Medical Classification Systems: Meeting

Pursuant to Pub. L. 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: NCVHS Subcommittee on Medical Classification Systems.

Time and Date: 9 a.m.-5 p.m., May 16, 1995.

Place: Room 703A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, D.C. 20201.

Status: Open.

Purpose: The subcommittee will discuss: the procedure classification systems for managed care; replacement for the International Classification of Diseases-9-Clinical Modification, Volume III, revision of Physicians' Current Procedural Terminology 4; and discuss the subcommittee's work plan.

Contact Person for More Information:

Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436-7050.

Dated: April 13, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-9619 Filed 4-18-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 94N-0299]

Plasmalab Donor Centers, Inc.; Revocation of U.S. License No. 1072-001

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 1072-001) and the product license issued to Plasmalab Donor Centers, Inc., doing business as Douglas Plasmalab, for the manufacture